Clinical Trial Update: A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. [Phase 2]

View source ↗

Summary

A prospective, single-arm Phase II trial evaluating Tafolecimab plus Sintilimab with chemotherapy in advanced or metastatic driver gene-negative non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)
• Tafolecimab

Snippet

Sponsor: Jinghui Wang | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING